Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05228795
Other study ID # Soh-Med-22-01-29
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2022
Est. completion date December 1, 2022

Study information

Verified date January 2022
Source Sohag University
Contact Nagwa Ahmed, Lecturer
Phone 01017415996
Email nagwa.sadek@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Lung carcinoma is the second most common cancer and a leading cause of cancer-related mortality worldwide. In Egypt, lung carcinoma ranks the 5th among all cancer cases. Malignant mesothelioma is an aggressive neoplasm that arises from mesothelial cells which form the lining of the pleural. There is a strong resemblance between epithelioid mesothelioma and lung adenocarcinoma, some of peripheral lung adenocarcinoma or SCC present with pleurotropic growth like mesothelioma. Glypican-1 (GPC1) is one the six glypican family members. It is one of cell surface heparan sulfate proteoglycans that acts as a growth factor signaling. The aim of this study is to evaluate the immunohistochemical expression of Glypican-1 in pleural epitheloid mesothelioma, lung adenocarcinoma and lung SCC


Description:

Lung carcinoma is the second most common cancer and a leading cause of cancer-related mortality worldwide, comprising almost 20% of all cancer deaths. In Egypt, lung carcinoma ranks the 5th among all cancer cases. It is more common in males than females, and most people diagnosed at the age of 65 years or older. The main risk factor of lung malignancy is tobacco smoking. There are two main histologic variants of lung carcinoma, non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC represents more than 80% of all lung carcinomas. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) and large cell carcinoma; of which lung adenocarcinoma is the most common subtype representing about 40%. Specific therapies can be offered to patients based on the histological and molecular status of primary tumors. Therefore, an accurate differentiation between solid predominant lung adenocarcinoma and poorly differentiated lung SCC has become increasingly indispensable; the accurate discrimination of these two main histological types is required for gene-targeted therapy. Malignant mesothelioma is an aggressive neoplasm that arises from mesothelial cells which form the lining of the pleural, pericardial, and peritoneal cavities. Majority of malignant mesothelioma, approximately 85%, occur in pleural cavity and most of the remainder arising in the peritoneum. In the United States around 3,000 new cases are diagnosed each year. In Egypt, pleural malignant tumors formed 1.3% of total malignant tumors. Pleural mesothelioma is the most frequent primary pleural malignant tumor forming more than half of the cases. The main risk factor for pleural mesothelioma is exposure to asbestos. Other risk factors may include; radiation exposure, old age, male gender and exposure to certain other minerals. Malignant mesothelioma is divided into three histologic variants that include: epithelioid, sarcomatoid and biphasic variants. Epithelioid variant is the most common subtype representing 70% of malignant mesothelioma. There is a strong resemblance between epithelioid mesothelioma and lung adenocarcinoma, some of peripheral lung adenocarcinoma or SCC present with pleurotropic growth like mesothelioma. The prognosis and management of epithelioid mesothelioma differ from lung carcinoma, so accurate diagnosis of mesothelioma is necessary. Glypican-1 (GPC1) is one the six glypican family members. It is one of cell surface heparan sulfate proteoglycans that acts as a growth factor signaling. It plays role in the control of cell division and growth regulation. It is encoded by GPC1 gene located at 2q37. It contains 588 amino acids with three predicted heparan sulfate chains. It has been evaluated as a potential target for cancer therapy. Many studies have shown that GPC1 is crucial for efficient cancer cell growth, metastasis and angiogenesis. Glypican-1 overexpression has previously been reported in breast cancer, pancreatic cancer and glioma. Studies evaluating the expression of Glypican-1 in pleural mesothelioma and lung carcinoma are deficient. Knowledge about its potential value in differentiation between pleural epithelioid mesothelioma, lung adenocarcinoma and SCC needs further elucidation. Aim of This Work: The aim of this study is to evaluate the immunohistochemical expression of Glypican-1 in pleural epitheloid mesothelioma, lung adenocarcinoma and lung SCC, and to correlate its expression with some known clinico-pathological parameters, to evaluate its diagnostic and prognostic role.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 1, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients with pleural epithelioid mesothelioma and lung adenocarcinoma and SCC who underwent surgery Exclusion Criteria: - Patients received pre-operative chemotherapy or radiotherapy. - Patients with insufficient clinical data. - Specimens with extensive necrosis - Tiny specimens which are insufficient for accurate diagnosis.

Study Design


Locations

Country Name City State
Egypt Faculty of Medicine, Sohag University Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary evaluate the immunohistochemical expression of Glypican-1 in pleural epitheloid mesothelioma, lung adenocarcinoma and lung SCC Immunohistochemical study 1 month
Primary to correlate its expression with some known clinico-pathological parameters, to evaluate its diagnostic and prognostic role. Statistical analysis 1 month
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04028570 - A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection N/A
Recruiting NCT05005429 - Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma Phase 2
Not yet recruiting NCT06310993 - Exercise to Boost Immunity in Advanced Cancer N/A
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Active, not recruiting NCT04300244 - Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma Phase 2
Recruiting NCT05278975 - Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma Phase 1/Phase 2
Not yet recruiting NCT04804410 - Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues N/A
Recruiting NCT04214015 - A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
Completed NCT05404022 - Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years N/A